Screening and Prostate-Cancer Mortality in a Randomized European Study

Abstract

PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)